NASDAQ | TSX: ACB
EDMONTON, AB, April 28,
2023 /PRNewswire/ - Aurora Cannabis Inc. (the
"Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian
company opening the world to cannabis, and a leading manufacturer
and supplier of dried flower for medical patients worldwide, today
announced the expansion of its portfolio in Germany with the launch of two new cannabis
flower products for patients. Pedanios 27/1 FRG CA and Pedanios
29/1 SRD CA are dried cannabis flower with high
tetrahydrocannabinol (THC) content. With these new therapeutic
options now available, the Company will better meet the individual
medical needs of its patients.
"The addition of these two high-THC products to our German
portfolio gives physicians even more options to provide patients
individually tailored treatments," says Dr. Axel Gille, President of Aurora Europe. "We are committed to bringing
high quality, consistent and innovative cannabis products to our
patients in Germany and throughout
Europe."
Providing patients with a broad spectrum of cannabis products
and formats is important to individualized and patient-specific
care. With this portfolio expansion, Aurora solidifies its
international market-leading position in medical cannabis.
Pedanios 27/1 FRG CA is medical cannabis flower from the Farm
Gas cultivar, with a THC content of about 27% and a cannabidiol
(CBD) content of <1%. This cultivar is known for its complex
aromas and fruity undertones.
Pedanios 29/1 SRD CA is medical cannabis flower from the
Sourdough cultivar, with approximately 29% THC and <1% CBD. Both
Farm Gas and Sourdough are proprietary cultivars developed by
Aurora's leading science and innovation business, Occo. They are
grown to the highest quality standards under EU GMP certified
conditions, hang-dried, hand finished, and hand bottled, resulting
in an exceptional product.
In addition, the Company announced it has filed a final short
form base shelf prospectus with securities regulators in each of
the provinces of Canada, except
Quebec, and a corresponding shelf
registration statement on Form F–10 with the United States
Securities and Exchange Commission.
This news release does not constitute an offer of any securities
for sale.
About Aurora
Aurora is opening the world to cannabis, serving both the
medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Whistler, Being and Greybeard, as well
as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. as
well as international brands, Pedanios, Bidiol and CraftPlant.
Aurora also has a controlling interest in Bevo Farms Ltd.,
North America's leading supplier
of propagated agricultural plants. Driven by science and
innovation, and with a focus on high-quality cannabis products,
Aurora's brands continue to break through as industry leaders in
the medical, performance, wellness and adult recreational markets
wherever they are launched. Learn more at www.auroramj.com and
follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, the expansion of the
Company's medical cannabis product portfolio in Germany and continued supply into that market,
and the associated benefits for patients and the Company, including
the expected impact on the Company's market share in international
medical cannabis.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances and that could
cause actual events, results, level of activity, performance,
prospects, opportunities or achievements to differ materially from
those projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's estimates of
consumer demand in Canada and in
jurisdictions where the Company exports, expectations of future
results and expenses, the risk of successful integration of
acquired business and operations, management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises,
including COVID-19, and other risks, uncertainties and factors set
out under the heading "Risk Factors" in the Company's annual
information form dated September 20,
2022 (the "AIF") and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR at
www.sedar.com and filed with and available on the SEC's
website at www.sec.gov. The Company cautions that the list of
risks, uncertainties and other factors described in the AIF is not
exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-expands-medical-cannabis-portfolio-in-germany-new-flower-varieties-for-patients-with-high-thc-needs-301811162.html
SOURCE Aurora Cannabis Inc.